BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.
| Product | Description | |
|---|---|---|
| GDC-0339 | GDC-0339, also called as SCHEMBL14801965, is a selective inhibitor of BaF3 PIM1 that has the potential for treatment of cancer. BaF3 PIM1: IC50= 43.6 nM; PIM1 LC-3K: IC50= 0.04 nM. Synonyms: 5-amino-N-[5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methylpyrazol-4-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamideGDC-0339; GDC 0339; GDC0339; SCHEMBL14801965BDBM110706CS-4775; HY-16976; CS 4775; HY 16976; CS4775; HY16976; US8614206, 139. CAS No. 1428569-85-0. Molecular formula: C20H22F3N7OS. Mole weight: 465.50. |  |
| GDC-0349 | GDC-0349 is a small molecule anticaner drug candidate, being developed by Genentech. As of July 2012, Genentech has filed phase I trial of GDC-0349 for evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma. Synonyms: GDC-0349; GDC 0349; GDC0349; RG7603. CAS No. 1207360-89-1. Molecular formula: C24H32N6O3. Mole weight: 452.559. | |
| GDC-0425 | This active molecular is an selective Checkpoint kinase 1 (Chk1) inhibitors and it enhances gemcitabine efficacy in tumor xenograft models. GDC-0425 was safe and yielded responses in patients with a variety of cancers. In Oct 2013, GDC 0425 was in phase I trials for Solid tumours and Lymphoma (late-stage disease) in USA and France. In May 2014, Genentech completed a phase I trial in Lymphoma and Solid tumours (late-stage disease) in USA and France. Uses: Solid tumours and lymphoma. Synonyms: GDC-0425; GDC 0425; GDC0425; 5-((1-ethylpiperidin-4-yl)oxy)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile; RG-7602; RG 7602; RG7602. Grade: 98%. CAS No. 1200129-48-1. Molecular formula: C18H19N5O. Mole weight: 321.38. | |
| GDC046 | GDC046 is a potent, selective, and orally bioavailable inhibitor of TYK2 with Ki of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM for TYK2, JAK1, JAK2, and JAK3, respectively. Synonyms: GDC-046; GDC 046. CAS No. 1258292-64-6. Molecular formula: C16H13Cl2N3O2. Mole weight: 350.20. | |
| GDC-0575 | GDC-0575 is a highly-selective, potent and oral small-molecule Chk1 inhibitor (IC50 = 1.2?nM). Uses: Protein kinase inhibitors. Synonyms: ARRY-575; RG7741; GDC0575. Grade: ≥98%. CAS No. 1196541-47-5. Molecular formula: C16H20BrN5O. Mole weight: 378.27. | |
| GDC0575 monohydrochloride | GDC0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. Synonyms: GDC0575 hydrochloride; ARRY-575 hydrochloride; (R)-N-(4-(3-Aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide hydrochloride. Grade: 95%. CAS No. 1196504-54-7. Molecular formula: C16H21BrClN5O. Mole weight: 414.73. | |
| GDC-0623 | GDC-0623 is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. Synonyms: GDC0623; GDC-0632; GDC 0632; G868; G 868; G-868. CAS No. 1168091-68-6. Molecular formula: C16H14FIN4O3. Mole weight: 456.216. | |
| GDC-0810 (ARN-810) | GDC-0810, also known as ARN-810 and RG6046, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. Synonyms: GDC0810; GDC 0810; GDC-0810; ARN810; ARN 810; ARN-810; RG6046; RG-6046; RG 6046. Grade: 98%. CAS No. 1365888-06-7. Molecular formula: C26H20ClFN2O2. Mole weight: 446.91. | |
| GDC-0834 | GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human. Synonyms: GDC-0834; GDC0834; GDC 0834. CAS No. 1133432-46-8. Molecular formula: C33H36N6O3S. Mole weight: 596.74. | |
| GDC-0837 | GDC-0834 is a small molecule inhibitor of Btk potentially useful in the treatment of RA and lymphoid malignancies. Administration of GDC-0834 (30 -- 100 mg/kg) in a rat CIA model induced a decrease of ankle swelling and reduction of morphologic pathology in a dose-dependent manner. Synonyms: GDC-0837; GDC 0837; GDC0837. CAS No. 1133432-49-1. Molecular formula: C33H36N6O3S. Mole weight: 596.74. | |
| GDC-0853 | GDC-0853 is a Bruton's tyrosine kinase (BTK) inhibitor originated by Genentech. GDC-0853 can inhibit the activity of BTK and prevent the activation of the B-cell antigen receptor (BCR) signaling pathway. This leads to the inhibition of the growth of malignant B-cells that overexpress BTK. Phase III clinical trials for the treatment of Multiple sclerosis and Phase II clinical trials for the treatment of Chronic urticaria and Systemic lupus erythematosus are on-going. Uses: Rheumatoid arthritis; autoimmune disorders. Synonyms: Fenebrutinib; RG 7845; RG7845; GDC0853; RG-7845; GDC 0853; (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one. Grade: 98%. CAS No. 1434048-34-6. Molecular formula: C37H44N8O4. Mole weight: 664.81. | |
| GDC-0879 | GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor. In GDC-0879-treated mice, both cell line- and patient-derived BRAF(V600E) tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant KRAS-expressing tumors. Despite the involvement of activated RAF signaling in RAS-induced tumorigenesis, decreased time to progression was observed for some KRAS-mutant tumors following GDC-0879 administration. Moreover, striking differences were noted for RAF and MEK inhibition across a panel of 130 tumor cell lines. Whereas GDC-0879-mediated efficacy was associated strictly with BRAF(V600E) status, MEK inhibition also attenuated proliferation and tumor growth of cell lines expressing wild-type BRAF (81% KRAS mutant, 38% KRAS wild type). The responsiveness of BRAF(V600E) melanoma cells to GDC-0879 could be dramatically altered by pharmacologic and genetic modulation of phosphatidylinositol 3-kinase pathway activity. These data suggest that GDC-0879-induced signaling changes are dependent on the point of oncogenic activation within the RAS network. Taken together, these studies increase our understanding of the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition and have implications for therapeutic intervention in the clinic. Synonyms: GDC0879; GDC-0879; GDC 0879. CAS No. 905281-76-7. Molecular formula | |
| GDC-0917 | CUDC-427, also known as, GDC-0917, is an orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic CUDC-427 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains. Synonyms: GDC-0917; GDC0917; GDC 0917; CUDC-427; CUDC427; CUDC-427. Grade: 0.98. CAS No. 1446182-94-0. Molecular formula: C29H36N6O4S. Mole weight: 564.705. | |
| GDC-0927 | GDC-0927 (SRN-927) is a selective oral estrogen receptor degrader (SERD) in a phase I clinical trial for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer. Study shows well tolerability and clinical effect. Uses: The potential therapy of breast cancer caused by estrogen disorder. Synonyms: SRN-927; SRN 927; SRN927; GDC-0927; GDC 0927; GDC0927. CAS No. 1642297-01-5. Molecular formula: C28H28FNO4. Mole weight: 461.52. | |
| GDC-0927 Racemate | GDC-0927 Racemate is an estrogen receptor degrader, which can effectively inhibit ER-α activity with an IC50 of 0.2 nM. It is used to study ER-related diseases. Synonyms: SRN-927 Racemate; 2H-1-Benzopyran-6-ol, 2-[4-[2-[3-(fluoromethyl)-1-azetidinyl]ethoxy]phenyl]-3-(3-hydroxyphenyl)-4-methyl-. Grade: ≥95%. CAS No. 1443983-36-5. Molecular formula: C28H28FNO4. Mole weight: 461.52. | |
| GDC0941 | GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K that inhibits p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM. Synonyms: 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; GDC-0941; GDC 0941; GDC0941; RG7321; RG-7321; RG 7321; GNE0941; GNE-0941; GNE 0941; Pictrelisib; Pictilisib. CAS No. 957054-30-7. Molecular formula: C23H27N7O3S2. Mole weight: 513.635. | |
| GDC-0941 dimethanesulfonate | GDC-0941 dimethanesulfonate is a potent inhibitor of PI3Kα/δ with modest selectivity against p110β and p110γ. It is a novel selective class I phosphatidylinositol-3-kinase (PI3K) inhibitor. It is designed to bind the ATP-binding pocket of PI3K and to prevent formation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3), a second messenger that transmits PI3K downstream signals. It causes growth inhibition in a variety of cancer cell lines, including A2780, MDA-MB-361, PC3, and U87MG. It also inhibits the growth of trastuzumab-sensitive and -resistant HER2-amplied cancer cells which harbor p110( mutations or PTEN loss. It also reduces tumor volume in different xenograft models. Synonyms: GDC-0941 dimethanesulfonate; GDC 0941 dimethanesulfonate; GDC0941 dimethanesulfonate; Pictilisib dimethanesulfonate; GDC-0941 (2 MeSO3H salt). Grade: >98%. CAS No. 957054-33-0. Molecular formula: C25H35N7O9S4. Mole weight: 705.85. | |
| GDC-0994 | GDC-0994, also known as RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival. Uses: Antineoplastic agents. Synonyms: GDC0994; GDC 0994; RG7842; RG-7842; RG 7842; Ravoxertinib. CAS No. 1453848-26-4. Molecular formula: C21H18ClFN6O2. Mole weight: 440.863. | |
| GDC-1971 | GDC-1971 is a potent allosteric SHP2 inhibitor for the treatment of RTK/RAS-driven tumors. Synonyms: Spiro[benzofuran-2(3H),4'-piperidin]-3-amine, 1'-[3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-, (3R)-; GDC1971; SHP-1971; (R)-1'-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4'-piperidin]-3-amine; NSC-841576; (3R)-1'-[3-(3,4-Dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-3H-spiro[1-benzofuran-2,4'-piperidin]-3-amine; Migoprotafib. Grade: ≥95%. CAS No. 2377352-49-1. Molecular formula: C25H26N8O. Mole weight: 454.54. | |
| GDC-4379 | GDC-4379, an inhibitor of JAK1, can be used for the study of asthma. Synonyms: N-(3-(5-chloro-2-(difluoromethoxy)phenyl)-1-(2-(dimethylamino)-2-oxoethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. CAS No. 2252277-73-7. Molecular formula: C21H18ClF2N7O3. Mole weight: 489.86. | |
| GDC-6036 | GDC-6036 is a selective inhibitor of KRAS G12C that blocks downstream signaling, and exhibits antineoplastic activity. Synonyms: Divarasib; E6S21PVT91; GDC6036; RG6330; 1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one; 1-((3S)-4-((7m)-7-(6-Amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one; 1-{(3S)-4-[(7M)-7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}quinazolin-4-yl]-3-methylpiperazin-1-yl}prop-2-en-1-one; 2-Propen-1-one, 1-((3S)-4-((7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl)-6-chloro-8-fluoro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)-4-quinazolinyl)-3-methyl-1-piperazinyl)-. CAS No. 2417987-45-0. Molecular formula: C29H32ClF4N7O2. Mole weight: 622.06. | |
| GDN | GDN, known as Growth Differentiation Factor, serves as a pivotal factor in cellular proliferation and differentiation processes. Its therapeutic applications extend to a wide array of medical conditions, such as oncological disorders and cardiovascular anomalies. GDN's innate ability to stimulate tissue healing and rejuvenation solidifies its significance in the realm of biomedical sciences. Synonyms: Glyco-diosgenin; 2-[2-[(3β,25R)-Spirost-5-en-3-yloxy]ethyl]-1,3-propanediyl bis[4-O-α-D-glucopyranosyl-β-D-glucopyranoside]; glyco-diosgenin (GDN); (2R,2'R,3S,3'S,4S,4'S,5R,5'R,6R,6'R)-6,6'-(((2R,2'R,3S,3'S,4R,4'R,5R,5'R,6R,6'R)-((2-(2-(((4S,5'R,6aR,6bS,8aS,8bR,9S,10R,11aS,12aS,12bS)-5',6a,8a,9-tetramethyl-1,3,3',4,4',5,5',6,6a,6b,6',7,8,8a,8b,9,11a,12,12a,12b-icosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-yl)oxy)ethyl)propane-1,3-diyl)bis(oxy))bis(4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-6,3-diyl))bis(oxy))bis(2-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol). Grade: >99%. CAS No. 1402423-29-3. Molecular formula: C56H92O25. Mole weight: 1165.31. | |
| GDP-2F-Fuc ammonium salt | A competitive inhibitor of fucosyltransferases FUT3, FUT5, FUT6 and FUT7 with Ki values in low micromolar range. This fluorinated GDP-fucose analog inhibits oligosaccharide core fucosylation of N-linked glycans in animal and plant cells. Synonyms: GDP-2-deoxy-2-fluoro-L-fucose ammonium salt. Molecular formula: C16H30FN7O14P2. Mole weight: 625.39. | |
| GDP366 | GDP366 is a novel small molecule compound which potently and selectively inhibited the expression of both survivin and Op18. GDP366 induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Synonyms: 1-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-3-(3-methylphenyl)urea; GDP 366; GDP-366; GDP366. CAS No. 501698-03-9. Molecular formula: C20H17N5OS. Mole weight: 375.45. | |
| GDP-6-deoxy-a-D-talose | GDP-6-deoxy-a-D-talose. Molecular formula: C16H23N5Na2O15P2. Mole weight: 633.31. | |
| GDPβS | GDPβS has been found to exhibit activities as an inhibitor of G-coupled protein. Synonyms: Guanosine-5'-(β-thio)-diphosphate, Sodium salt. Grade: ≥ 90 % by HPLC. Molecular formula: C10H15N5O10P2S (free acid). Mole weight: 459.26 (free acid). | |
| GDP-b-L-glucose ammonium salt | GDP-b-L-glucose ammonium salt is an extensively employed compound, serving as a pivotal tool for examining enzymatic activities and metabolic pathways linked to glucose. This product facilitates profound insights into the intricate mechanisms underlying glucose-related disorders, including diabetes. Synonyms: Guanosine 5'-Diphosphate b-L-glucose ammonium salt; Guanosine 5'-(Trihydrogen Diphosphate) b-L-glucose ammonium salt. Molecular formula: C16H31N7O16P2. Mole weight: 639.40. | |
| GDP-D-galactose | GDP-D-galactose, an indispensable biochemical molecule within the biomedical industry, encompasses a pivotal role in enzymatic reactions. As a substrate for glycosylation-involved enzymes, this vital compound becomes essential for the synthesis of diverse glycoproteins and glycolipids. CAS No. 41432-88-6. Molecular formula: C16H25N5O15P2. Mole weight: 605.34. | |
| GDP-D-glucose disodium salt | GDP-D-glucose sodium salt, a biochemical component for metabolic pathway study and intracellular signaling, plays an imperative role in glucose metabolism. Its potential therapeutic agent property for various diseases is highlighted in recent diabetes and cancer research. And its acknowledged proficiency in regulating the cell differentiation and proliferation further consolidates its prominence. Synonyms: Guanosine-5-diphosphoglucose disodium salt; GDP-Glc disodium salt; Guanosine 5'-(trihydrogen diphosphate), P'-β-D-glucopyranosyl ester, disodium salt. CAS No. 103301-72-0. Molecular formula: C16H23N5O16P2.2Na. Mole weight: 649.31. | |
| GDP-D-mannose diammonium salt | GDP-D-mannose diammonium salt is a pivotal compound within the biomedical field assuming the fundamental position as a forerunner for the synthesis of GDP-mannose. This molecule is crucially engaged in glycosylation mechanisms. Molecular formula: C16H23N5O16P2.N2H8. Mole weight: 639.4. | |
| GDP-D-mannose disodium salt | GDP-D-mannose disodium salt is an invaluable compound, playing a pivotal role in the research of disorders pertaining to compromised glucose metabolism. Functioning as a critical intermediate within biosynthetic pathways, it specifically facilitates the synthesis of sugar nucleotides. Synonyms: Guanosine 5-diphospho-D-mannose disodium salt; GDP-Man; Guanosine 5'-(trihydrogen diphosphate), P'-D-mannopyranosyl ester, disodium salt. CAS No. 103301-73-1. Molecular formula: C16H23N5O16P2Na2. Mole weight: 649.30. | |
| GDP-Gel / GDP-Agarose | GDP-Gel is the GDP coupled to a polymeric gel by the terminal phosphate, which can be used in the affinity purification of fucosyltransferases. Synonyms: Guanosine- 5'- O- diphosphate, immobilized on a polymeric matrix. | |
| GDP-L-fucose | GDP-L-fucose is a pivotal biomolecule acting as a precursory compound to facilitate the synthesis of fucose-containing glycoconjugates implicated in diverse cellular phenomena. Its exceptional significance lies in the research of glycosylation patterns, evaluation of protein functioning repercussions and investigation into possible therapeutic approaches targeting conditions like cancer and inflammation. Synonyms: GDP-b-L-fucose; Guanosine 5-diphospho-b-L-fucose; GDP-Fucose; Guanosine diphosphofucose; Guanosine 5'-diphospho-beta-L-fucopyranose; guanosine 5'-[3-(6-deoxy-beta-L-galactopyranosyl) dihydrogen diphosphate]. Grade: 95%. CAS No. 15839-70-0. Molecular formula: C16H25N5O15P2. Mole weight: 589.34. | |
| GDP-L-fucose diammonium salt | GDP-L-fucose diammonium salt is an indispensable compound, serving as a vital substrate for fucosyltransferase. This compound intricately contributes to the biosynthesis of fucosylated glycans. Molecular formula: C15H23N5O15P2.N2H8. Mole weight: 623.41. | |
| GDP-L-fucose disodium salt | Substrate for fucosyltransferase. Synonyms: Guanosine 5'-pyrophosphate, β-L-fucopyranosyl ester Disodium Salt; Guanosine pyrophosphate, L-fucosyl ester Disodium Salt; Guanosine diphosphofucose Disodium Salt; Guanosine diphosphate fucose Disodium Salt; Guanosine 5'-pyrophosphate, L-fucosyl ester Disodium Salt; Guanosine 5'-diphospho-β-L-fucose Disodium Salt; GDP-Fucose Disodium Salt. Grade: ≥95%. CAS No. 148296-47-3. Molecular formula: C16H23N5O15P2Na2. Mole weight: 633.31. | |
| GDP-L-galactose sodium salt | GDP-L-galactose sodium salt, an indispensable element in the field of biomedicine, assumes a pivotal function in the amalgamation of Vitamin C, thereby facilitating the amelioration of scurvy and associated ailments. This efficacious product showcases its potential in enhancing general well-being and mitigating deficiencies stemming from insufficient levels of Vitamin C. Synonyms: Guanosine 5-diphosphate-L-galactose. Grade: 95%. CAS No. 6815-91-4. Molecular formula: C16H23N5Na2O16P2. Mole weight: 649.30. | |
| GDP - lyophilized | Guanosine 5'-diphosphate could be used to study cell signaling related to G-coupled protein receptors as well as some GTPases. Synonyms: Guanosine-5'-diphosphate, Sodium salt. Grade: ≥ 90 % by HPLC. CAS No. 43139-22-6. Molecular formula: C10H15N5O11P2(free acid). Mole weight: 443.20 (free acid). | |
| GDP-mannose | GDP-mannose. Synonyms: Guanosine 5'-(trihydrogen diphosphate), P'-α-D-mannopyranosyl ester; Guanosine 5'-(trihydrogen pyrophosphate), mono-α-D-mannopyranosyl ester; Guanosine 5'-pyrophosphate, α-D-mannopyranosyl ester; GDP-D-mannose; GDP-α-D-mannose; Guanosine 5'-(trihydrogen pyrophosphate) mono-D-mannosyl ester; Guanosine 5'-(trihydrogen pyrophosphate) monomannopyranosyl ester; Guanosine 5'-diphosphate D-mannose; Guanosine 5'-pyrophosphate D-mannosyl ester; Guanosine 5'-pyrophosphate α-D-mannosyl ester; Guanosine diphosphate mannose; Guanosine diphosphomannose. Grade: ≥90%. CAS No. 3123-67-9. Molecular formula: C16H25N5O16P2. Mole weight: 605.34. | |
| GeA-69 | GeA-69 is a cell-permeable allosteric inhibitor of PARP-14 macrodomain 2 with Kd of 860 nM. Synonyms: GeA-69; 2143475-98-1; N-(2-(9H-Carbazol-1-yl)phenyl)acetamide; CHEMBL4226393; N-[2-(9H-Carbazol-1-yl)phenyl]acetamide; GeA69; GeA 69; BCP31007; BDBM50461016; AKOS037515677; BS-16620; HY-108708; CS-0030139; S0732; D81049. CAS No. 2143475-98-1. Molecular formula: C20H16N2O. Mole weight: 300.35. | |
| Gedatolisib (PF-05212384, PKI-587) | Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Phase 2. Synonyms: PKI587; PKI-587; PKI 587; PF05212384; PF-05212384; PF 05212384; PF5212384; PF-5212384; PF 5212384; Gedatolisib. Grade: >98%. CAS No. 1197160-78-3. Molecular formula: C32H41N9O4. Mole weight: 615.73. | |
| Gedunin | Gedunin is a naturally occurring Hsp90 inhibitor. Induces Hsp90-dependent client protein degradation and displays antiproliferative activity in vitro (IC50 values are 3.22, 8.84 and 16.8 μM in SKBr3, MCF-7 and CaCo-2 cancer cell lines respectively). It also exhibits antimalarial activity against P. falciparum (IC50 values are 0.14 and 3.1 μM in parasite development and [3H]-hypoxanthine uptake assays respectively). Grade: >98%. CAS No. 2753-30-2. Molecular formula: C28H34O7. Mole weight: 482.57. | |
| Gefapixant | Gefapixant is a P2X3 receptor (P2X3R) antagonist with IC50s of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. It is under a clinical trial for the treatment of chronic cough. Synonyms: AF-219; MK-7264. CAS No. 1015787-98-0. Molecular formula: C14H19N5O4S. Mole weight: 353.4. | |
| Gefarnate | Gefarnate is a drug used for the treatment of gastritis and gastric ulcer, in vivo, the instillation of gefarnate reduced corneal epithelial damage from desiccation in a dose-dependent fashion. Besides Gefarnate has been proposed for use in the treatment of dry eye syndrome. Synonyms: [(2E)-3,7-dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate; Farnesylacetate, Geranyl; Gefarnate; Gefarnil; Gepharnate; Geranyl Farnesylacetate; Ulco. CAS No. 51-77-4. Molecular formula: C27H44O2. Mole weight: 400.64. | |
| Gefitinib 3,4-Difluoro Impurity HCl | Gefitinib 3,4-Difluoro Impurity HCl. Grade: > 95%. CAS No. 184475-68-1. Molecular formula: C22H25F2N4O3Cl. Mole weight: 466.92. | |
| Gefitinib 4-Desfluoro Impurity HCl | Gefitinib 4-Desfluoro Impurity HCl. Grade: > 95%. Molecular formula: C22H26Cl2N4O3. Mole weight: 465.38. | |
| Gefitinib Chloro Impurity | Gefitinib Chloro Impurity. Grade: > 95%. Molecular formula: C16H21Cl2N3O3. Mole weight: 374.27. | |
| Gefitinib EP Impurity A | An impurity of Gefitinib. Gefitinib is a first-generation EGFR tyrosine kinase inhibitor used primarily to treat non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations. Synonyms: Gefitinib Impurity 12; 7-Methoxy-6-(3-morpholin-4-ylpropoxy)-1H-quinazolin-4-one; 7-Methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(3H)-one; 7-Methoxy-6-[3-(4-morpholinyl)propoxy]-4(3H)-quinazolinone; 7-Methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one; 7-Methoxy-6-(3-morpholinopropoxy)quinazolin-4-one; 7-Methoxy-6-[3-(4-morpholinyl)propoxy]quinazolin-4(3H)-one. Grade: ≥95%. CAS No. 199327-61-2. Molecular formula: C16H21N3O4. Mole weight: 319.36. | |
| Gefitinib EP Impurity B | An impurity of Gefitinib. Gefitinib is a first-generation EGFR tyrosine kinase inhibitor used primarily to treat non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations. Synonyms: N-(4-Chloro-3-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(4-Chloro-3-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; 3-Deschloro-4-desfluoro-4-chloro-3-fluoro Gefitinib; Gefitinib Imp. B (EP); Gefitinib Impurity B. Grade: ≥95%. CAS No. 1603814-04-5. Molecular formula: C22H24ClFN4O3. Mole weight: 446.90. | |
| Gefitinib hydrochloride | Gefitinib Hcl(ZD-1839 Hcl) is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Synonyms: Iressa hydrochloride; ZD 1839 hydrochloride; ZD-1839 hydrochloride; ZD1839 hydrochloride. Grade: >98%. CAS No. 184475-55-6. Molecular formula: C22H25Cl2FN4O3. Mole weight: 483.36. | |
| Gefitinib Impurity 1 | Gefitinib Impurity 1. Synonyms: 2-Amino-4-methoxy-5-(3-morpholin-4-ylpropoxy)-benzamide. Grade: > 95%. CAS No. 246512-44-7. Molecular formula: C15H23N3O4. Mole weight: 309.37. | |
| Gefitinib Impurity 3 | Gefitinib Impurity 3. Grade: > 95%. Molecular formula: C15H22N2O5. Mole weight: 310.35. | |
| Gefitinib Impurity HCl | Gefitinib Impurity HCl. Synonyms: 3-Deschloro-4-Desfluoro-4-Chloro-3-Fluoro Gefitinib HCl. Grade: > 95%. Molecular formula: C22H25Cl2FN4O3. Mole weight: 483.37. | |
| Gefitinib Impurity I | Gefitinib Impurity I. Grade: > 95%. Molecular formula: C29H37ClFN5O4. Mole weight: 574.10. | |
| Gefitinib Impurity II | Gefitinib Impurity II. Synonyms: N-(3-chloro-4-fluorophenyl)-6 ,7-dimethoxyquinazolin-4-amine. Grade: > 95%. CAS No. 153437-78-6. Molecular formula: C16H13ClFN3O2. Mole weight: 333.75. | |
| Gefitinib Impurity IV | Gefitinib Impurity IV. Grade: > 95%. Molecular formula: C22H24Cl2N4O3. Mole weight: 463.37. | |
| Gefitinib Impurity VI | Gefitinib Impurity VI is Gefitinib intermediate. Synonyms: 4-(3-Chloropropyl)morpholine; 1-Chloro-3-morpholinopropane; 3-(Morpholin-4-yl)propyl Chloride; 3-Chloro-1-(morpholin-4-yl)propane; 3-Morpholinopropyl Chloride; NSC 28831; NSC 38889; N-(3-Chloropropyl)morpholine. Grade: > 95%. CAS No. 7357-67-7. Molecular formula: C7H14ClNO. Mole weight: 163.65. | |
| Gefitinib Impurity VII | An impurity of Gefitinib. Gefitinib is an EGFR inhibitor. It is used for the treatment of certain breast, lung and other cancers. Synonyms: 3,4-Dihydro-4-oxo-6-acetoxy-7-methoxyquinazoline; 6-(Acetyloxy)-7-methoxy-4(3H)-quinazolinone; 3,4-Dihydro-7-methoxy-4-oxoquinazolin-6-yl acetate; Gefitinib interMidiate IV; 7-Methoxy-4-oxo-3,4-dihydroquinazolin-6-yl acetate. Grade: > 95%. CAS No. 179688-53-0. Molecular formula: C11H10N2O4. Mole weight: 234.21. | |
| Gefitinib Impurity VIII | Gefitinib Impurity VIII. Synonyms: 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinol 6-acetate; 4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate; 6-Quinazolinol,4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-, 6-acetate; Gefitinib intermediate VI. Grade: > 95%. CAS No. 788136-89-0. Molecular formula: C17H13ClFN3O3. Mole weight: 361.76. | |
| Gefitinib Impurity X | Gefitinib Impurity X. Synonyms: 6-Acetoxy-4-chloro-7-methoxyquinazoline; 4-Chloro-6-acetoxy-7-methoxyquinazoline; 4-Chloro-7-methoxy-6-quinazolinol 6-acetate; Gefitinib interMediate V; 6-Quinazolinol, 4-chloro-7-Methoxy-, 6-acetate; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropox. Grade: > 95%. CAS No. 230955-75-6. Molecular formula: C11H9ClN2O3. Mole weight: 252.66. | |
| Gefitinib N-Oxide | Gefitinib N-oxide is the N-oxide derivative of Gefitinib. Synonyms: Gefitinib Morpholine N-oxide; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-oxido-4-morpholinyl)propoxy]-4-quinazolinamine; 4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine 4-oxide. Grade: > 95%. CAS No. 847949-51-3. Molecular formula: C22H24ClFN4O4. Mole weight: 462.91. | |
| Gellan gum | Gellan gum is a water-soluble polysaccharide produced by the bacterium Sphingomonas elodea. Gellan gum is composed of repeating units of tetrasaccharide, specifically glucose, rhamnose, and glucuronic acid. It is widely used as a gelling agent, thickener, and stabilizer in various food, pharmaceutical, and industrial applications due to its ability to form gels and its versatility in different conditions. Synonyms: Bistop MN-HM; Gel-Gro; Gellan; Gelrite; Gelrite gellan gum; Gelup K-S (F); Gelzan; Gelzan CM; Grindsted Gellan DAI 90; Kelcogel; Kelcogel 700; Kelcogel AF; Kelcogel AFT; Kelcogel CG; Kelcogel CG-LA; Kelcogel DGA; Kelcogel HF-B; Kelcogel Hi-pHive; Kelcogel HMB; Kelcogel HP-T; Kelcogel HT-P; Kelcogel hydriodide-pHive; Kelcogel PS; LT 100 (stabilizer); Neosoft J; Neosoft J 40; Newgelin LG-10; OMY; Phytagel; PS 60; Roeper 700f; Takaragen FE 01; TayaGel. CAS No. 71010-52-1. | |
| Gemcabene | Gemcabene is an orally available lipid-lowering small molecule designed to target known lipid metabolic pathways, as an adjunctive therapy to reduce LDL-C, hsCRP and triglycerides (TGs). Currentl, Gemcabene is under Phase-II clinical trials in Hypertriglyceridaemia in USA. Synonyms: 6-(5-carboxy-5-methyl-hexoxy)-2,2-dimethyl-hexanoic acid; gemcabene; 6,6'-oxybis(2,2-dimethylhexanoic acid); PD72953; PD 72953; PD-72953. Grade: >98%. CAS No. 183293-82-5. Molecular formula: C16H30O5. Mole weight: 302.41. | |
| Gemcadiol | Gemcadiol is a new antilipemic drug with lipid-regulating properties. Uses: Antilipemic. Synonyms: CI-720; CI 720; CI720; 2,2,9,9-Tetramethyl-1,10-decanediol. Grade: ≥98%. CAS No. 35449-36-6. Molecular formula: C14H30O2. Mole weight: 230.389. | |
| Gemcitabine-5'-diphosphate | A diphosphorylated derivative of Gemcitabine and has been found to exhibit potent activities as an inhibitor of ribonucleotide reductases (RNRs). Synonyms: 2'-deoxy-2',2'-difluorocytidine 5'-(trihydrogen diphosphate). Grade: ≥ 95 % by HPLC. CAS No. 116371-66-5. Molecular formula: C9H13F2N3O10P2. Mole weight: 423.16. | |
| Gemcitabine-5'-triphosphate | A triphosphorylated derivative of Gemcitabine and has been found to exhibit potent activities as a cytotoxic agent and induce apoptosis. Synonyms: 2',2'-Difluorocytidine-5'-triphosphate. Grade: ≥ 95 % by HPLC. Molecular formula: C9H14N3O13P3F2. Mole weight: 503.14. | |
| Gemcitabine alpha-anomer | Gemcitabine alpha-anomer is an anomer of Gemcitabine. Gemcitabine is a nucleoside analog used in chemotherapy to treat cancers including testicular cancer, breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. Synonyms: Gemcitabine EP Impurity B; 4-Amino-1-(2-deoxy-2,2-difluoro-α-D-erythropentofuranosyl)pyrimidin-2(1H)-one; Gemcitabine α-anomer; 4-Amino-1-(2-deoxy-2,2-difluoro-α-D-erythro-pentofuranosyl)-2(1H)-pyrimidinone; Gemcitabine Impurity B; 1'-Epi Gemcitabine; 4-Amino-1-((2S,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 1-(2,2-Difluoro-2-deoxy-α-D-ribofuranosyl)cytosine; α-Gemcitabine; Gemcitabine hydrochloride EP Impurity B. Grade: ≥95%. CAS No. 95058-85-8. Molecular formula: C9H11F2N3O4. Mole weight: 263.20. | |
| Gemcitabine (alpha-Isomer) Hydrochloride | Gemcitabine (alpha-Isomer) Hydrochloride is an α-Anomer of Gemcitabine. Gemcitabine is a nucleoside analogue used in chemotherapy. It treats cancers including testicular cancer, breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer and bladder cancer. Synonyms: 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-2,2-difluoro-α-D-erythro-pentofuranosyl)-, hydrochloride (1:1); Gemcitabine EP Impurity B hydrochloride; 4-Amino-1-(2-deoxy-2,2-difluoro-α-D-erythropentofuranosyl)pyrimidin-2(1H)-one hydrochloride; Gemcitabine α-anomer hydrochloride; Gemcitabine Impurity B hydrochloride; 1'-Epi Gemcitabine hydrochloride; 1-(2,2-Difluoro-2-deoxy-α-D-ribofuranosyl)cytosine hydrochloride; α-Gemcitabine hydrochloride. Grade: >95%. CAS No. 122111-05-1. Molecular formula: C9H12F2N3O4Cl. Mole weight: 299.65. | |
| Gemcitabine Diphosphate Choline | Gemcitabine derivative. An antineoplastic agent. Synonyms: Gemcitabine 5'-Diphosphate Choline. Grade: 95%. CAS No. 1643126-46-8. Molecular formula: C14H24F2N4O10P2. Mole weight: 508.31. | |
| Gemcitabine Diphosphate Triethylamine Salt | Gemcitabine Diphosphate is a Gemcitabine phosphorylated metabolite, an antineoplastic agent. Synonyms: 2'-Deoxy-2',2'-difluorocytidine 5'-(Trihydrogen Diphosphate) Triethylamine Salt; Gemcitabine 5'-Diphosphate Triethylamine Salt. Grade: 90%. Molecular formula: C27H58F2N6O10P2. Mole weight: 726.73. | |
| Gemcitabine elaidate | Gemcitabine elaidate (also known as CO-101; CP-4126) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Due to its lipophilicity, gemcitabine 5'-elaidic acid ester exhibits an increased cellular uptake and accumulation, resulting in an increased conversion to active metabolites, compared to gemcitabine. In addition, this formulation of gemcitabine may be less susceptible to deamination and deactivation by deoxycytidine deaminase. Synonyms: CO-101; CO101; CO 101; CP-4126; CP4126; CP 4126. CAS No. 210829-30-4. Molecular formula: C27H43F2N3O5. Mole weight: 527.654. | |
Our database is helping our users find suppliers everyday.
